Valsartan Does NOT Lower Uric Acid
Valsartan has a neutral effect on serum uric acid levels and should not be expected to provide uric acid-lowering benefits. Unlike losartan, which has well-documented uricosuric properties, valsartan does not significantly affect renal handling of uric acid 1, 2.
Key Evidence
FDA Drug Label Findings
The FDA label for valsartan explicitly states: "In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid" 1. This is definitive evidence from the drug's official prescribing information.
Clinical Research Confirmation
A randomized, placebo-controlled trial specifically examining valsartan's effect on renal uric acid handling in healthy subjects found no differences in uric acid clearance, fractional excretion, or excretion rates with valsartan versus placebo 2. The study demonstrated that valsartan did not affect any component of renal uric acid transport—neither presecretory reabsorption, tubular secretion, nor postsecretory reabsorption.
Mechanistic Understanding
Laboratory studies show that valsartan can inhibit uric acid transporters (OAT1, OAT3, OAT4) at certain concentrations 3, but these effects do not translate into clinically meaningful uric acid changes in practice. This contrasts sharply with losartan, which has both transporter effects AND clinical uric acid-lowering efficacy.
Clinical Implications for Gout Management
When Hypertension Coexists with Gout
The 2017 EULAR guidelines specifically recommend losartan or calcium channel blockers for hypertension in gout patients—NOT valsartan 4. This recommendation reflects the evidence that among angiotensin receptor blockers, only losartan has demonstrated meaningful uricosuric effects.
ARB Class Effect Does NOT Exist
A comprehensive review confirms that uric acid reduction is NOT a class effect of ARBs 5. Among available agents:
- Losartan: Clear evidence of uric acid lowering (~0.3 mg/dL reduction) 6, 7
- Valsartan: Neutral effect 1, 2, 5
- Candesartan: Neutral or negative effect 5
- Azilsartan: Negative impact (raises uric acid) 5
- Irbesartan: Neutral or modest positive effect 5
Important Exception: Sacubitril/Valsartan
Sacubitril/valsartan (the combination product) DOES lower uric acid, but this effect appears attributable to the sacubitril component (neprilysin inhibition), not valsartan 8, 9, 10. Studies show:
- Sacubitril/valsartan reduced uric acid by 0.24 mg/dL versus enalapril in heart failure patients 9
- Switching from ARBs to sacubitril/valsartan decreased uric acid levels 8
- The effect correlates with improved eGFR 8
Practical Recommendations
For Hypertensive Patients with Hyperuricemia or Gout:
- Choose losartan as first-line ARB if an ARB is indicated 4, 11, 6, 7
- Avoid valsartan monotherapy if uric acid lowering is a treatment goal
- Consider sacubitril/valsartan in heart failure patients where both blood pressure control and modest uric acid reduction are desired 9, 10
- Do NOT rely on valsartan to counteract diuretic-induced hyperuricemia
Common Pitfall to Avoid:
Do not assume all ARBs have similar effects on uric acid. This misconception can lead to suboptimal drug selection in patients with both hypertension and gout. The evidence clearly distinguishes losartan from other ARBs in this regard.
When Valsartan is Already Prescribed:
If a patient is stable on valsartan for other indications (e.g., heart failure, post-MI) and develops hyperuricemia or gout, do NOT expect valsartan to help with uric acid management. Instead, initiate appropriate urate-lowering therapy (allopurinol, febuxostat, or probenecid) according to standard gout management guidelines 4, 11.